Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.30 |
| ▸ | SELE | P16581 | 1/20 | 0.30 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4050758 | 0.78 | P2RX7 (0.42) | SLC6A2SLC6A4P2RX7 | |
| SCHEMBL17080539 | 0.78 | HDAC6 (0.33) | SLC6A2SLC6A4KDM4CP2RX7 | |
| SCHEMBL5645623 | 0.74 | SLC6A2 (0.37) | SLC6A2SLC6A4KDM4C | |
| SCHEMBL17595736 | 0.68 | CCR1 (0.35) | P2RX7 | |
| SCHEMBL23104539 | 0.68 | P2RX7 (0.41) | SLC6A2SLC6A4P2RX7 | |
| SCHEMBL16679290 | 0.68 | P2RX7 (0.40) | P2RX7 | |
| SCHEMBL7015186 | 0.68 | P2RX7 (0.44) | SLC6A2SLC6A4P2RX7 | |
| SCHEMBL7055234 | 0.67 | ESR2 (0.48) | SLC6A2SLC6A4 | |
| SCHEMBL17080542 | 0.67 | SLC6A4 (0.41) | SLC6A2SLC6A4 | |
| SCHEMBL17080493 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3114126-B1 | 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-10-31 | — | — | EP | disclosed |
| US-10106544-B2 | 1,2-dihydro-3H-pyrrolo[1,2-C]imidazol-3-one derivatives and their use as antibacterial agents | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-10-23 | — | — | US | disclosed |
| US-20170107223-A1 | 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-04-20 | — | — | US | disclosed |
| EP-3114126-A1 | 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | Actelion Pharmaceuticals Ltd (CH) | 2017-01-11 | — | — | EP | disclosed |
| WO-2015132228-A1 | 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106544-B2 | 1,2-dihydro-3H-pyrrolo[1,2-C]imidazol-3-one derivatives and their use as antibacterial agents | CCNI, H1-0, H1-3 | SLC6A2 4532/4885SLC6A4 4784/4885KDM4C 2047/4885 |
| US-20170107223-A1 | 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | CCNI, H1-0, H1-3 | SLC6A2 4532/4885SLC6A4 4784/4885KDM4C 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.